Navigation Links
Interferon does not slow or stop hepatitis C from worsening, study finds
Date:11/9/2007

Interferon does not slow or halt the progression of chronic hepatitis C and advanced liver disease in patients who havent responded to previous attempts to eradicate the disease, a national study in which the Saint Louis University School of Medicine participated has found.

Patients in the trial who were treated with interferon did experience a significant decrease in viral levels and liver inflammation, but the trial unequivocally demonstrated that treatment with long-term pegylated interferon also called peginterferon does not prevent the worsening of liver disease in patients whove failed prior treatments.

The results are this study are very clear long-term therapy with peginterferon for those with chronic hepatitis C is not effective in preventing progression of liver disease for patients who did not respond to an initial course of treatment, said Adrian Di Bisceglie, M.D., professor of internal medicine at Saint Louis University School of Medicine and chairman of the trials steering committee.

Furthermore, the relatively high rate of liver disease progression about 30 percent over nearly four years indicates the potential severity of chronic hepatitis C and emphasizes the importance of the ongoing search for new and more effective treatments, Di Bisceglie added.

Results of the study were reported by Di Bisceglie at the annual meeting of the American Association for the Study of Liver Disease in Boston this week.

Hepatitis C infects more than 100 million people worldwide and as many as 4 million people in the U.S. It ranks with alcohol abuse as the most common cause of chronic liver disease and leads to some 1,000 liver transplants in the U.S. each year.

The randomized, multi-site study involved 1,050 patients with chronic hepatitis C whod failed prior treatments to eradicate the infection. All had advanced liver fibrosis a gradual scarring of the liver that puts patients at risk for progressive liver disease.

The trial assessed whether long-treatment with peginterferon prevented the patients from developing cirrhosis, liver failure or liver cancer. Roughly half of the patients in the study received 90 micrograms of peginterferon in weekly injections for 3.5 years. The other half, the control group, underwent the same follow-up and care as the treated patients, including liver biopsies, quarterly clinic visits and blood tests.

At the end of the study, while patients treated with interferon did have significantly lower blood levels of the hepatitis C virus and less liver inflammation, 34.1 percent of them had experienced one or more of the following outcomes: excess fluid in the abdomen; brain and nervous system damage; cirrhosis (for those who did not have it initially); liver cancer; or death. Of patients in the control group, 33.8 percent experienced one or more of the outcomes.

Among treated patients, adverse side effects had caused 17 percent to stop peginterferon after 18 months and 30 percent to stop treatment by the end of the trial.


'/>"/>

Contact: Donn Walker
dwalke18@slu.edu
314-977-8015
Saint Louis University
Source:Eurekalert

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Today, the ... , announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian ... TV Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is poised to once again host, Swirl, A Wine Tasting Event at ...
(Date:2/5/2016)... ... 05, 2016 , ... Regular gym users know the routine: each January, they ... access the treadmills. It’s a predictable trend. After the excesses of November and December, ... shape by joining gyms, starting new walking or running routines, or signing up for ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Amgen (NASDAQ: AMGN ... Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, ... . David W. Meline , executive vice president and ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
(Date:2/5/2016)... , Feb. 5, 2016  Patients in Alabama ... focused ultrasound (HIFU) therapy no longer have to travel out ... its partnership with Urology Centers of Alabama to ... FDA-cleared procedure for qualifying patients. Alabama ... in the treatment of prostate cancer using many different modalities. ...
(Date:2/5/2016)... , February 5, 2016 ... Research report states that the global active pharmaceuticals ingredients ... is predicted to reach US$185.9 bn by 2020. It ... from 2014 to 2020. The title of the report ... Manufactured, by Geography, and by Therapeutic Area) - Global ...
Breaking Medicine Technology: